HUYA Bioscience International
Business Services · California, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
12531 High Bluff Dr Ste 138, San Diego, ...Phone Number
(858) 798-8800Website
www.huyabio.comRevenue
$16.9 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
2
1
1
1
1
About HUYA Bioscience International
HUYA Bioscience International is a leader in globalizing China's biopharma innovation, focusing on accelerating the development of novel biopharmaceutical products. The company boasts the largest compound portfolio covering all major therapeutic areas, supported by a network of offices in the US, Japan, South Korea, Canada, Ireland, and across China. Through collaborations with biopharmaceutical, academic, and commercial organizations, HUYA provides faster, cost-effective, and lower-risk drug development solutions. Its extensive expertise makes it a preferred partner for maximizing product development value in global markets.Explore more
HUYA Bioscience International Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is HUYA Bioscience International your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Check if HUYA Bioscience International has recently received funding, and reach out quickly before it becomes old news!
Check out if HUYA Bioscience International is spiking on competitors!
Product Launch: Get notified when HUYA Bioscience International launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on HUYA Bioscience International recently announced quarterly report
Click to see if HUYA Bioscience International had a recent Job posting/layoffs
HUYA Bioscience International, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once HUYA Bioscience International has new funding data
Congratulate Masked Content for being promoted to Masked Content at HUYA Bioscience International
Recommended Actions
Reach out to Masked Content who joined HUYA Bioscience International as Masked Content
Find 3 more new buyers
Compare Similar Companies to HUYA Bioscience International
Compare insights from companies similar to HUYA Bioscience International, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
HUYA Bioscience Internati...
$16.9M
51-200
Private
<$5M
2004
MG
Mireille GillingsPresident & CEO & Chair Executive
Company Profile Activity
Activity Insights
HUYA Bioscience International is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
HUYA Bioscience International is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about HUYA Bioscience International.
HUYA Bioscience International financials insights
Gather financial insights about HUYA Bioscience International, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Debt
$350K
HUYA Bioscience International Tech Stack
A closer look at the technologies used by HUYA Bioscience International
See more technologies
Most Recent Scoops
New Hire
Executive Move
Executive Moves, New Hire
Project
A high-level source in Accounting has indicated that the organization is planning to begin initiatives related to accounts payable within three months. HUYA Bioscience International LLC is currently evaluating Bill. com. The organization is considering the use of a contingent workforce to support these efforts. The organization is considering automating the AP process as part of these initiatives.
Automation, Contingent Workforce, Accounting, Financial Planning, Billing & Invoice
Pain Point
Project
A high-level source in Accounting has indicated that the organization is planning to remediate challenges related to payroll.
Accounting, Compensation & Benefits
Pain Point
Project
A high-level source in Accounting has indicated that the organization is planning to remediate challenges related to enterprise resource planning (ERP) software.
Accounting, Business Development, Enterprise Software, Operating Systems
Pain Point
Project
Accounting
HUYA Bioscience International News & Media
HUYABIO INTL. PRESENTS POSITIVE CLINICAL RESULTS FROM HBI-3000 PHASE 2A CLINICAL TRIAL OF NOVEL MULTI-ION CHANNEL BLOCKER FOR ACUTE ATRIAL FIBRILLATION
Authors: Denis Roy1, Suzanne Romano2, Jay W. Mason3, Monica Wynn2, Charles Pollack4, Gary Elliot5, Mireille Gillings2, Jerome B. Riebman2 SAN DIEGO, April 24, 2025 /PRNewswire/ -- HUYABIO International today announced the presentation of new patient data for HBI-3000, a novel bioinspired...HUYABIO Validates Protective Mechanism for Antiarrhythmic Drug HBI-3000 in AF Patients, Paving the Way for a New Era in Atrial Fibrillation Treatment
HBI-3000 Aims to Fill Critical Gaps in Atrial Fibrillation Care; Key Data to be Presented at the American Heart Association Annual Meeting SAN DIEGO, Nov. 14, 2024 /PRNewswire/ -- HUYABIO International today announced the presentation of new patient data for HBI-3000, an antiarrhythmic...HUYABIO Presents Positive Phase 2 Data on HBI-8000 and Nivolumab Combination for Advanced Melanoma
Data supporting the potential for innovative combinations like HBI-8000 and nivolumab to reshape the future of melanoma treatment will be presented at the Society for Immunotherapy of Cancer Annual Meeting SAN DIEGO, Nov. 8, 2024 /PRNewswire/ -- HUYABIO International today announced it...HUYABIO INTERNATIONAL ANNOUNCES INITIATION OF HBI-3000 PHASE 2 TRIAL
SAN DIEGO, June 14, 2022 /PRNewswire/ -- HUYABIO International today announced that the first three patients had been dosed in an ongoing Phase 2 study of HUYABIO's novel drug for pharmacological cardioversion of atrial fibrillation (AF). Dr. Mireille Gillings, President, CEO & Executive...
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding HUYA Bioscience International
Sign Up For FreeTo access detailed company insights
HUYA Bioscience International is a leader in globalizing China's biopharma innovation, focusing on accelerating the development of novel biopharmaceutical products. The company boasts the largest compound portfolio covering all major therapeutic areas, supported by a network of offices in the US, Japan, South Korea, Canada, Ireland, and across Chin... Read More
